Evidence map›Paper›PMID 29802030›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2018

Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease.

Ron Brookmeyer, Nada Abdalla

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 4 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 4 syntheses or guidelines pooled it, 168 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Dementia risk factors and biomarkers in subjective cognitive decline: real world evidence from the monza brain health service.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ron BrookmeyerDepartment of Biostatistics, University of California, Los Angeles, CA, USA. Electronic address: rbrookmeyer@ucla.edu.
Nada AbdallaDepartment of Biostatistics, University of California, Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

Alzheimer's Disease Risks and Projections Using Multi-State Models with BiomarkersR21AG055361 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BROOKMEYER, RONALD S · 2017 to 2018
$424k
NIA NIH HHS R21 AG055361
6 · The paper itself

Abstract

introductionLifetime risks are the probabilities of progressing to Alzheimer's disease (AD) dementia during one's lifespan. Here, we report the first estimates of the lifetime and ten-year risks of AD dementia based on age, gender, and biomarker tests for preclinical disease.

methodsWe used a multistate model for the disease process together with US death rates.

resultsLifetime risks of AD dementia vary considerably by age, gender, and the preclinical or clinical disease state of the individual. For example, the lifetime risks for a female with only amyloidosis are 8.4% for a 90-year old and 29.3% for a 65-year old. Persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration have lifetime risks of AD dementia greater than 50%. DISCUSSION: Most persons with preclinical AD will not develop AD dementia during their lifetimes. Lifetime risks help interpret the clinical significance of biomarker screening tests for AD.

Indexed as

BiomarkersCognitive DysfunctionDementiaMortalityAgedAged, 80 and overAlzheimer DiseaseFemaleHumansMaleMiddle AgedRiskBiomarkersAlzheimer's diseaseLifetime risksPreclinicalPrediction

Identifiers

PMID29802030
PMCPMC6097953
OpenAlexW2804922289

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.